- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/00 - Antineoplastic agents
Patent holdings for IPC class A61P 35/00
Total number of patents in this class: 107944
10-year publication summary
|
2229
|
2456
|
4430
|
6314
|
6707
|
7825
|
9074
|
9793
|
9897
|
8595
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10623 |
1007 |
| The Regents of the University of California | 20289 |
913 |
| Genentech, Inc. | 4015 |
764 |
| F. Hoffmann-La Roche AG | 7933 |
748 |
| Bristol-myers Squibb Company | 4820 |
698 |
| Dana-Farber Cancer Institute, Inc. | 2623 |
688 |
| Board of Regents, The University of Texas System | 5938 |
616 |
| Memorial Sloan-Kettering Cancer Center | 1985 |
517 |
| AstraZeneca AB | 2858 |
516 |
| Merck Patent GmbH | 5759 |
501 |
| The Johns Hopkins University | 5751 |
487 |
| Centre National de La Recherche Scientifique | 10693 |
466 |
| Hoffmann-La Roche Inc. | 3533 |
462 |
| Amgen Inc. | 4258 |
451 |
| Incyte Corporation | 1037 |
447 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2911 |
426 |
| Pfizer Inc. | 3401 |
408 |
| Janssen Pharmaceutica N.V. | 3351 |
406 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3373 |
401 |
| Bayer Pharma AG | 1048 |
388 |
| Other owners | 96634 |